Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Results of a Feasibility and Phase II Study on Bortezomib (BTZ) in Pediatric Multiply Relapsed or Refractory Acute Lymphoblastic Leukemia: Complete Hematological Responses with a Modestly Intensive Regimen Including BTZ

Gertjan Kaspers, MD PhD, Denise Niewerth, MSc, Satianand Ramnarain, MSc, Andishe Attarbaschi, MD, André Baruchel, MD, Evelina S De Bont, MDPhD, Franca Fagioli, MD, Barbara De Moerloose, MD PhD, Karsten Nysom, MD, Giuseppe Palumbo, MD, Dirk Reinhardt, MD PhD, Pierre-Simon Rohrlich, MDPhD, Pauline Simon, MD, Arend von Stackelberg, MD, C. Michel Zwaan, MD PhD

Blood (2014) 124 (21): 2290.

https://doi.org/10.1182/blood.V124.21.2290.2290

Published: 2014

Journal Articles

The Novel Immunoproteasome Inhibitor PR-924: Anti-Leukemic Activity and Mechanisms Of Resistance

Denise Niewerth, MSc, Johan van Meerloo, MSc, Yehuda Assaraf, PhD, Gerrit Jansen, PhD, Tessa C Hendrickx, BSc, Christopher J. Kirk, Ph.D, Janet Anderl, MS, Sonja Zweegman, MD PhD, Jacqueline Cloos, PhD, Gertjan Kaspers, MD, PhD

Blood (2013) 122 (21): 3841.

https://doi.org/10.1182/blood.V122.21.3841.3841

Published: 2013

Journal Articles

Pharmacokinetic Results Of a Feasibility and Phase II Study (ITCC 021) On Bortezomib (BTZ) In Pediatric Relapsed ALL: Lack Of Significant Penetration Of BTZ In The Cerebrospinal Fluid

Gertjan Kaspers, MD, PhD, Ron Mathot, PharmD PhD, Satianand Ramnarain, MSc, Denise Niewerth, MSc, Franco Locatelli, MD, PhD, Eveline S.J.M De Bont, MD, PhD, Franca Fagioli, MD, Pierre Rohrlich, MD, Arend von Stackelberg, Michel Zwaan

Blood (2013) 122 (21): 1439.

https://doi.org/10.1182/blood.V122.21.1439.1439

Published: 2013

Journal Articles

Interferon-γ-Induced Upregulation of Immunoproteasome Subunit Assembly Overcomes Bortezomib Resistance of Leukemia Cell Lines Harbouring Bortezomib-Induced Mutations in Constitutive PSMB5

Denise Niewerth, MSc, Niels Franke, MD, Gerrit Jansen, PhD, Yehuda Assaraf, PhD, Johan van Meerloo, MSc, Christopher J Kirk, PhD, Sonja Zweegman, MD, PhD, Gertjan J.L. Kaspers, MD, PhD, Jacqueline Cloos, PhD

Blood (2012) 120 (21): 1346.

https://doi.org/10.1182/blood.V120.21.1346.1346

Published: 2012

Journal Articles

Sensitivity of Pediatric Acute Leukemia Cells to Bortezomib and Epoxyketone-Based Proteasome Inhibitors: Correlations with Proteasome Subunit Expression

Denise Niewerth, MSc, Niels Franke, MD, Gerrit Jansen, PhD, Johan van Meerloo, MSc, Yehuda Assaraf, Prof, Christopher J Kirk, Elena T Chan, Sonja Zweegman, MD, PhD, Gertjan J. Kaspers, MD, PhD, Jacqueline Cloos, PhD

Blood (2011) 118 (21): 1513.

https://doi.org/10.1182/blood.V118.21.1513.1513

Published: 2011

NARROW

Results of a Feasibility and Phase II Study on Bortezomib (BTZ) in Pediatric Multiply Relapsed or Refractory Acute Lymphoblastic Leukemia: Complete Hematological Responses with a Modestly Intensive Regimen Including BTZ

The Novel Immunoproteasome Inhibitor PR-924: Anti-Leukemic Activity and Mechanisms Of Resistance

Pharmacokinetic Results Of a Feasibility and Phase II Study (ITCC 021) On Bortezomib (BTZ) In Pediatric Relapsed ALL: Lack Of Significant Penetration Of BTZ In The Cerebrospinal Fluid

Interferon-γ-Induced Upregulation of Immunoproteasome Subunit Assembly Overcomes Bortezomib Resistance of Leukemia Cell Lines Harbouring Bortezomib-Induced Mutations in Constitutive PSMB5

Sensitivity of Pediatric Acute Leukemia Cells to Bortezomib and Epoxyketone-Based Proteasome Inhibitors: Correlations with Proteasome Subunit Expression

Email alerts

ASH Publications

American Society of Hematology

Results of a Feasibility and Phase II Study on Bortezomib (BTZ) in Pediatric Multiply Relapsed or Refractory Acute Lymphoblastic Leukemia: Complete Hematological Responses with a Modestly Intensive Regimen Including BTZ

The Novel Immunoproteasome Inhibitor PR-924: Anti-Leukemic Activity and Mechanisms Of Resistance

Pharmacokinetic Results Of a Feasibility and Phase II Study (ITCC 021) On Bortezomib (BTZ) In Pediatric Relapsed ALL: Lack Of Significant Penetration Of BTZ In The Cerebrospinal Fluid

Interferon-γ-Induced Upregulation of Immunoproteasome Subunit Assembly Overcomes Bortezomib Resistance of Leukemia Cell Lines Harbouring Bortezomib-Induced Mutations in Constitutive PSMB5

Sensitivity of Pediatric Acute Leukemia Cells to Bortezomib and Epoxyketone-Based Proteasome Inhibitors: Correlations with Proteasome Subunit Expression

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only